[ET Net News Agency, 15 March 2021] Daiwa Research lifted its target price for Sino
Biopharmaceutical (01177) to HK$12 from HK$11 and maintained its "buy" rating.
The research house cited Sino Biopharm's management targeting over 10% revenue growth
for those old generics in 2021. Anlotinib recorded double-digit revenue growth in the
first two months of 2021, resuming its robust growth momentum after the NRDL negotiation;
Daiwa estimated its revenue to rise to CNY5.2bn in 2021 from CNY4.2bn in 2020.
New drugs to be launched in 2021 include PD-1 mAb (expect to receive approval by June)
and several other major generics, including lenvatinib, afatinib, rituximab, adalimumab,
coagualation factor VIII, etc. Overall, Daiwa forecast 20% core earnings growth in 2021,
net of Sinovac's contribution. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01177 SINO BIOPHARM
Nominal 
2.340 -0.090 (-3.704%) Research Report
15/03/2021 10:01
{I-bank focus}Daiwa lifts Sino Biopharm (01177) to HK$12
| Remark: | Real time quote last updated: 19/04/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |